Neurocognitive performance and negative symptoms: Are they equal in explaining disability in schizophrenia outpatients?

Villalta-Gil, Victòria; Vilaplana, Míriam; Ochoa, Susana; Haro, Josep María; Dolz, Montserrat; Usall, Judit; Cervilla, Jorge A.

doi:10.1016/j.schres.2006.06.013

Cited by 76 publications

(37 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the associative striatum establishes major connections with the frontal lobe (Lehericy et al, 2004). The frontal cortex has been implicated in the neurocognitive deficits seen in schizophrenia (Villalta-Gil et al, 2006), deficits which are also present in subjects with prodromal symptoms and FEP patients (Cadenhead, 2002;Jahshan et al, 2010). The associative striatum, and especially the precommissural dorsal caudate, has shown the highest D 2 receptor availability after acute pharmacologically induced dopamine depletion in antipsychotic-free patients with schizophrenia (Kegeles et al, 2010).…”

Section: Summary Of Main Resultsmentioning

confidence: 99%

Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis

Fuente‐Sandoval

León-Ortíz

Favila

et al. 2011

Neuropsychopharmacol

208

157

View full text Add to dashboard Cite

The glutamatergic and dopaminergic systems are thought to be involved in the pathophysiology of schizophrenia. Their interaction has been widely documented and may have a role in the neurobiological basis of the disease. The aim of this study was to compare, using proton magnetic resonance spectroscopy ( 1 H-MRS), glutamate levels in the precommissural dorsal-caudate (a dopamine-rich region) and the cerebellar cortex (negligible for dopamine) in the following: (1) 18 antipsychotic-naïve subjects with prodromal symptoms and considered to be at ultra high-risk for schizophrenia (UHR), (2) 18 antipsychotic-naïve first-episode psychosis patients (FEP), and (3) 40 age-and sex-matched healthy controls. All subjects underwent a 1 H-MRS study using a 3Tesla scanner. Glutamate levels were quantified and corrected for the proportion of cerebrospinal fluid and percentage of gray matter in the voxel. The UHR and FEP groups showed higher levels of glutamate than controls, without differences between UHR and FEP. In the cerebellum, no differences were seen between the three groups. The higher glutamate level in the precommissural dorsal-caudate and not in the cerebellum of UHR and FEP suggests that a high glutamate level (a) precedes the onset of schizophrenia, and (b) is present in a dopamine-rich region previously implicated in the pathophysiology of schizophrenia.

show abstract

Section: Summary Of Main Resultsmentioning

confidence: 99%

Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis

Fuente‐Sandoval

León-Ortíz

Favila

et al. 2011

Neuropsychopharmacol

208

157

View full text Add to dashboard Cite

show abstract

“…Negative symptoms were found to be correlated with generalized cognitive deficit (Bilder et al, 2000;Heydebrand et al, 2004), or specific cognitive domains including executive function (Donohoe et al, 2006), memory (Villalta-Gil et al, 2006) and processing speed (Leeson et al, 2010). However, previous research consistently demonstrated only modest associations between negative symptoms and cognition with limited explained variance (Green and Neuchterlein, 1999;Harvey et al, 2006b).…”

Section: Introductionmentioning

confidence: 93%

Relationship between diminished expression and cognitive impairment in first-episode schizophrenia: A prospective three-year follow-up study

Chang

Hui

et al. 2014

Schizophrenia Research

View full text Add to dashboard Cite

“…Among these, the two consensus components are affective flattening and diminished motivation (Blanchard and Cohen, 2006; Moller, 2007). Negative symptoms have been found to be the major predictor of functional outcome in patients with schizophrenia (Brune et al, 2011; Gonzalez-Blanch et al, 2010; Rabinowitz et al, 2012; Shamsi et al, 2011; Villalta-Gil et al, 2006) and are important for their ultimate qualify of life and functional recovery (Alvarez-Jimenez et al, 2012; Gorecka and Czernikiewicz, 2004). …”

Section: Introductionmentioning

confidence: 99%

Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: A meta-analysis

Shi

Cheung

et al. 2014

Psychiatry Research

116

View full text Add to dashboard Cite

This study sought to determine the moderators in the treatment effect of repetitive transcranial magnetic stimulation (rTMS) on negative symptoms in schizophrenia. We performed a meta-analysis of prospective studies on the therapeutic application of rTMS in schizophrenia assessing the effects of both low-frequency and high-frequency rTMS on negative symptoms. Results indicate that rTMS is effective in alleviating negative symptoms in schizophrenia. The effect size was moderate (0.63 and 0.53, respectively). The effect size of rTMS on negative symptoms in sham-controlled trials was 0.80 as measured by the SANS and 0.41 as measured by the PANSS. A longer duration of illness was associated with poorer efficacy of rTMS on negative symptoms. A 10 Hz setting, at least 3 consecutive weeks of treatment, treatment site at the left dorsolateral prefrontal cortex (DLPFC) and a 110% motor threshold (MT) were found to be the best rTMS parameters for the treatment of negative symptoms. The results of our meta-analysis suggest that rTMS is an effective treatment option for negative symptoms in schizophrenia. The moderators of rTMS on negative symptoms included duration of illness, stimulus frequency, duration of illness, position and intensity of treatment as well as the type of outcome measures used.

show abstract

Neurocognitive performance and negative symptoms: Are they equal in explaining disability in schizophrenia outpatients?

Cited by 76 publications

References 40 publications

Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis

Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis

Relationship between diminished expression and cognitive impairment in first-episode schizophrenia: A prospective three-year follow-up study

Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: A meta-analysis

Contact Info

Product

Resources

About